Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia [1]

Leukemia Research

Volumn 29, Issue 6, 2005, Pages 719-720

  Chng, Wee J ^a   Tan, Leonard H C ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; BONE MARROW APLASIA; CANCER GRADING; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG DOSE REDUCTION; HUMAN; KARYOTYPE; LETTER; MALE; NEUTROPENIA; ONSET AGE; PANCYTOPENIA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA;

EID: 18044380078     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.11.017     Document Type: Letter

References (5)

1. S.G. O'Brien, F. Guilhot, R.A. Larson, I. Gathmann, M. Baccarani, and F. Cervantes Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia N Engl J Med 348 2003 994 1004
2. A. Horikoshi, K. Takei, and S. Sawada Effects of low dose of imatinib to CML patients Leuk Res 27 2003 1167
3. Y. Tsutsumi, H. Kanamori, H. Yamato, N. Ehira, T. Miura, and T. Kawamura Monitoring of plasma imatinib concentration for the effective treatment of CML Leuk Res 28 2004 1117 1118
4. M.W.N. Deininger, S.G. O'Brien, J.M. Ford, and B.J. Druker Practical management of patients with chronic myeloid leukaemia receiving imatinib J Clin Oncol 8 2003 1637 1647
5. K. Bartolovic, S. Balabanov, U. Hartman, M. Komor, A.M. Boehmler, and H.J. Buhring Inhibitory effect of imatinib on normal progenitor cells in vitro Blood 102 2004 523 529